Short
Ritter Pharmaceuticals basically dead?
-75% Ritter Pharmaceuticals Inc -after the company's Phase 3 trial of RP-G28 for lactose intolerance failed to demonstrate statistical significance in its pre-specified endpoint
Views and opinions for informational purposes only. Remember, past performance is no guarantee of future results.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Views and opinions for informational purposes only. Remember, past performance is no guarantee of future results.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.